Literature DB >> 19395199

Radicality of resection and survival after multimodality treatment is influenced by subsite of locally recurrent rectal cancer.

Miranda Kusters1, Raphaëla C Dresen, Hendrik Martijn, Grard A Nieuwenhuijzen, Cornelis J H van de Velde, Hetty A van den Berg, Regina G H Beets-Tan, Harm J T Rutten.   

Abstract

PURPOSE: To analyze results of multimodality treatment in relation to subsite of locally recurrent rectal cancer (LRRC). METHOD AND MATERIALS: A total of 170 patients with LRRC who underwent treatment between 1994 and 2008 were studied. The basic principle of multimodality treatment was preoperative (chemo)radiotherapy, intended radical surgery, and intraoperative radiotherapy. The subsites of LRRC were classified as presacral, posterolateral, (antero)lateral, anterior, anastomotic, or perineal. Subsites were related to radicality of the resection, local re-recurrence rate, distant metastasis rate, and cancer-specific survival.
RESULTS: R0 resections were achieved in 54% of the patients, and 5-year cancer-specific survival was 40.5%. The worst outcomes were seen in presacral LRRC, with only 28% complete resections and 19% 5-year survival (p = 0.03 vs. other subsites). Anastomotic LRRC resulted in the most favorable outcomes, with 77% R0 resections and 60% 5-year survival (p = 0.04). Generally, if a complete resection was achieved, survival improved, except in posterolateral LRRC. Local re-recurrence and metastasis rate were lowest in anastomotic LRRC.
CONCLUSIONS: Classification of the subsite of LRRC is a predictor of potentially resectable and consequently curable disease. Treatment of posterior LRRC imposes poor results, whereas anastomotic LRRC location shows superior results.

Entities:  

Mesh:

Year:  2009        PMID: 19395199     DOI: 10.1016/j.ijrobp.2009.01.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increased risk associated with distal margin.

Authors:  F A Calvo; F Rivas; C V Sole; M Gómez-Espí; R Herranz; E Del Valle; M Rodríguez; E Alvarez
Journal:  Clin Transl Oncol       Date:  2013-10-16       Impact factor: 3.405

Review 2.  Patterns of local recurrence in rectal cancer after a multidisciplinary approach.

Authors:  Jose M Enríquez-Navascués; Nerea Borda; Aintzane Lizerazu; Carlos Placer; Jose L Elosegui; Juan P Ciria; Adelaida Lacasta; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

3.  Impact of anatomic location on locally recurrent rectal cancer: superior outcome for intraluminal tumour recurrence.

Authors:  Johannes Klose; Ignazio Tarantino; Thomas Schmidt; Thomas Bruckner; Yakup Kulu; Tobias Wagner; Martin Schneider; Markus W Büchler; Alexis Ulrich
Journal:  J Gastrointest Surg       Date:  2015-03-31       Impact factor: 3.452

4.  Intensity-modulated radiation therapy for pelvic oligo-recurrence from rectal cancer: long-term results from a single institution.

Authors:  Xiang-Gao Zhu; Yong-Heng Li; Xiao-Fan Li; Yong Cai
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

5.  Multidisciplinary therapy for patients with locally oligo-recurrent pelvic malignancies.

Authors:  Claudio V Sole; Felipe A Calvo; Pedro Alvarez de Sierra; Rafael Herranz; Luis Gonzalez-Bayon; Jose Luis García-Sabrido
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-10       Impact factor: 4.553

6.  Prognostic value of quality of life and pain in patients with locally recurrent rectal cancer.

Authors:  Y Nancy You; Halim Habiba; George J Chang; Miguel A Rodriguez-bigas; John M Skibber
Journal:  Ann Surg Oncol       Date:  2010-12-04       Impact factor: 5.344

7.  Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.

Authors:  D-S Sun; J-D Zhang; L Li; Y Dai; J-M Yu; Z-Y Shao
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

8.  Impact of multimodal therapy in locally recurrent rectal cancer.

Authors:  Y N You; J M Skibber; C-Y Hu; C H Crane; P Das; E S Kopetz; C Eng; B W Feig; M A Rodriguez-Bigas; G J Chang
Journal:  Br J Surg       Date:  2016-03-02       Impact factor: 6.939

9.  Salvage high-dose-rate interstitial brachytherapy for locally recurrent rectal cancer: long-term follow-up results.

Authors:  Masahiro Morimoto; Fumiaki Isohashi; Yasuo Yoshioka; Osamu Suzuki; Yuji Seo; Toshiyuki Ogata; Yuichi Akino; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  Int J Clin Oncol       Date:  2013-06-01       Impact factor: 3.402

Review 10.  Intentionally curative treatment of locally recurrent rectal cancer: a systematic review.

Authors:  Pieter J Tanis; Annemiek Doeksen; J Jan B van Lanschot
Journal:  Can J Surg       Date:  2013-04       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.